AIM
MRNS

Acrospire Investment Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Acrospire Investment Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-424
Closed -$3K – 2606
2017
Q1 		$3K Sell
424
-3,157
-88% -$17K ﹤0.01% 2089
2016
Q4 		$14K Buy
+3,581
New +$16.7K 0.01% 1879

Other funds holding MRNS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acrospire Investment Management's MRNS Position: Q2 2017 in Review

Acrospire Investment Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2017, closing a stake of 424 shares — an estimated $3K sold.

Acrospire Investment Management first reported a position in MRNS in Q4 2016 and held it in 2 quarters. The position peaked at $14K in Q4 2016. 24 funds tracked by Wall St. Rank hold MRNS as of Q2 2017.

  • Acrospire Investment Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 424 Marinus Pharmaceuticals, Inc shares in Q2 2017, an estimated $3K.
  • Acrospire Investment Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Marinus Pharmaceuticals, Inc position peaked at $14K in Q4 2016.
  • 24 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.